%0 Journal Article
%T Utility of Human Epidermal Growth Factor Receptor 2 (HER2) Retesting of Histologic Grade 3 Invasive Breast Carcinomas
%A Elizabeth Cureton
%A Rebecca Gologorsky
%A Veronica Shim
%J Archive of "The Permanente Journal".
%D 2019
%R 10.7812/TPP/18-088
%X American Society of Clinical Oncology and College of American Pathologists guidelines recommend repeated evaluation of human epidermal growth factor receptor 2 (HER2) status on surgical specimens from patients with a diagnosis by core-needle biopsy of Grade 3, HER2-negative invasive tumors of the breast. However, there are limited data to support reflexive testing
%K breast cancer
%K HER2
%K herceptin
%K hormone receptor
%K trastuzumab
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326556/